A global leader in digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
Global
Joined July 2015
- Tweets278
- Following206
- Followers279
- Likes163
Adherium partners with Florida Lung, Asthma & Sleep Specialists to roll out Hailie® Smartinhaler® platform across Central Florida, giving clinicians real-time insight into asthma and COPD.
bit.ly/3UHhVRv
$ADR #Asthma #COPD
CEO Dawn Bitz and Chief Commercial Officer John Perry recently provided an investor update on #Adherium's pathway to value-based care in the US.
Here's the replay: bit.ly/ADR_VBC_briefing
$ADR #digitalhealth #respiratory #healthcare #remotepatientmonitoring #valuedbasedcare
@Adherium has today released the revised time for its investor webinar - 10:30am AEST 25 June 2026. CEO Dawn Bitz and CCO John Perry will outline how the Company is positioning itself to secure Value Based Care (VBC) contracts. Register now: bit.ly/ADRJuneWebinar2026 $ADR
Equity analysts MST Access have released a report highlighting Adherium’s major value.
Read the full report: bit.ly/4dK20st
$ADR #Adherium #digitalhealth #respiratoryhealth #asthma #innovation #healthcare
Adherium has presented the first dataset from its RPM program, showing only 8.3% of asthma patients demonstrated optimal inhaler technique using objective Hailie® Smartinhaler® data.
Read the ASX release: bit.ly/4u7d7jX
$ADR #RPM #DigitalHealth #Asthma
Adherium has appointed John Perry as Chief Commercial Officer to lead integrated global commercial operations and support expansion into value-based respiratory care.
Read the ASX release: bit.ly/4o2vyVL
$ADR #DigitalHealth #RPM #ValueBasedCare
Two independent studies were presented at the ATS 2026 International Conference, featuring data using Adherium’s Hailie® Smartinhaler® technology.
Together, they reinforce the role of objective respiratory monitoring in improving patient outcomes.
🔗 bit.ly/3PYyUMJ
Today is World Asthma Day. The future of asthma care lies in making invisible visible - using continuous data to better understand and support how patients manage their condition. @Adherium is leading this shift. #WorldAsthmaDay
@Adherium has today released its quarterly report for the period ending 31 March 2026, highlighting continued acceleration in recurring RPM revenue and commercial execution.
Read the ASX release: bit.ly/4mY5zy9
Adherium has announced new real-world results from the iCARE study, showing a 67% reduction in hospitalisations and 46% reduction in total cost of care for patients using the Hailie® Smartinhaler® platform.
Read the ASX release: bit.ly/46QwqFv
@Adherium has released a sales update highlighting continued commercial momentum behind its Hailie® Smartinhaler® platform and Remote Patient Monitoring (RPM) model.
Read the ASX release: bit.ly/4cGfNA1
CEO Dawn Bitz recently provided an investor update on Adherium’s accelerating commercial progress, interim data from the landmark iCARE Study, and the recently completed capital raise.
Here’s the replay: youtu.be/DRUzspwesKo
Adherium (ASX:ADR) has announced that it has received firm commitments for a total of $6.70 million under the Placement and institutional component of the Accelerated Pro-Rata Non-Renounceable Entitlement Offer (ANREO).
Read the ASX announcement: bit.ly/4rmeNFz
Adherium has today announced a capital raising of up to approximately A$7.52 million through a Placement and a 1-for-1.5 pro-rata accelerated non-renounceable Entitlement Offer.
Read the ASX announcement: bit.ly/3OaZXDs
